Novartis's Sandoz strikes deal for biosimilar of Herceptin

Novartis's Sandoz division has struck a deal with Taiwan's EirGenix Inc to market a biosimilar version of Roche's Herceptin that is now in late-stage development to treat some cancer tumors.

from Reuters: Health https://reut.rs/2PzOpae
via IFTTT

• Tweet
• Share
• Share
• Share
• Share